Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients With Mild Alzheimer's Disease

Authors not listed

vTv Therapeutics · 2016

Abstract

This is an open-label extension study in patients with mild Alzheimer's disease who have completed participation in the azeliragon Phase 3 (STEADFAST) trial. Patients will receive azeliragon 5 mg/day for up to 2 years.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-13 MST

Cite this

APA
Anonymous. (2016). Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients With Mild Alzheimer's Disease. <em>vTv Therapeutics</em>. https://clinicaltrials.gov/study/NCT02916056
Vancouver
Anonymous. Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients With Mild Alzheimer's Disease. vTv Therapeutics. 2016.
BibTeX
@misc{anon2016OpenLa, title = {Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients With Mild Alzheimer's Disease}, author = {Anonymous}, journal = {vTv Therapeutics}, year = {2016}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings